-
How Protocol Design Decisions Shape Recruitment, Data Quality & Study Startup
Protocol amendments, recruitment delays, data quality issues, and operational bottlenecks are often discovered during study execution. That does not necessarily mean they originate there. In many cases, the underlying issue can be traced back to protocol decisions that seemed reasonable during study design but created unintended downstream consequences once sites, participants, and study teams began…
-
What Is an eCRF?
Understanding what an eCRF is and how it fits into your clinical trial starts with recognizing its role in accurate, protocol-driven data collection, then taking intentional steps to choose the right tools for your study. You should consider the following: Clinical trials generate enormous amounts of data. Clinicians need to be able to record every…
-
EDC Software: The Best Clinical Trial Software for CROs
Choosing the right EDC software for your CRO starts with understanding how the platform you select affects your data quality, operational efficiency, and ability to scale—then taking deliberate steps to find the right fit. For best results, you should consider the following: Choose a platform built for how CROs actually operate: Look for software that…
-
How Contract Research Organizations (CROs) Can Optimize Their Workflows
Clinical trials are becoming more complex, more distributed, and more data-heavy. For contract research organizations (CROs), that means greater operational strain across every aspect of study execution. The demand for speed, precision, and transparency is rising, while margins and timelines continue to shrink. To stay competitive, CROs need to do more than keep up, they…
-
Customizing EDC Workflows for Specialty Pharma and Rare Disease Trials
Why Rare Disease and Specialty Pharma Trials Need Custom Workflows Rare disease and specialty pharma trials operate under very different conditions than large, conventional studies. Instead of enrolling hundreds or thousands of patients at a limited number of clinical sites, these studies often include only a small number of participants spread across wide geographic areas.…
-
The Role of EDC in Real-Time Decision-Making During Adaptive Trials
Adaptive clinical trials are built to respond to evidence as it emerges, allowing researchers to make changes midstream without compromising study integrity. Adjustments to dosing, enrollment, or treatment arms can be made based on interim analyses, creating opportunities for faster timelines, better resource allocation, and improved patient safety. This promise depends on one critical factor:…
-
Why Scalable EDC Systems Matter in Global Pharmaceutical Trials
Clinical development rarely moves in a straight line. Programs expand across countries, add cohorts, refine eligibility criteria, and shift timelines in response to emerging data. For pharmaceutical sponsors, the common thread is scale. The ability to move from a handful of sites to hundreds, from one language to many, and from a single study to…
-
How EDC Powers End-to-End Data Management in Pharma-Sponsored Clinical Trials
Electronic data capture, or EDC, continues to be a constant in modern clinical research studies. For pharmaceutical sponsors running complex, multi-phase programs, EDC can help connect protocol design, site operations, data review, and submission preparation. Done well, it gives every stakeholder a single, reliable source of truth. It speeds startup, reduces risk, and builds a…
-
How EDC-Based SAE Reporting Reduces Time to Detection and Response in Clinical Trials
Serious adverse events (SAEs) are among the most critical data points collected during a clinical trial. The timeliness and accuracy of SAE reporting can mean the difference between a manageable issue and a significant safety crisis. As regulatory expectations increase and trial designs grow more complex, sponsors and CROs need tools that accelerate safety workflows…
-
How EDC Software Minimizes Bias in Clinical Trials
The Impact of Bias on Clinical Trials and Patient Safety Bias, despite best efforts and best intentions, continues to impact clinical research. There’s the so-called “sponsorship effect,” where, in a recent study, psychiatric drugs were reported to be about 50% more effective in trials that were funded by the drug’s manufacturer. It may be natural…
